Literature DB >> 7033381

Immune response to phosphorylcholine. IX. Characterization of hybridoma anti-TEPC15 antibodies.

M K Wittner, M A Bach, H Köhler.   

Abstract

Hybridoma antibodies against the PC-binding T15 BALB/c myeloma protein were raised by cell fusion with anti-T15 A/He immune cells. The idiotype specificity of these monoclonal anti-T15 antibodies was determined with a panel of different myeloma and hybridoma immunoglobulins. Two types of anti-T15 antibodies are seen. One reacts with a number of different IgA myeloma proteins and with serum IgA of certain strains of mice; this reactivity most likely is due to allotypy. The other group consists of anti-T15 antibodies that are specific for the T15 idiotype and are therefore termed anti-idiotypic. The bindings of the anti-idiotype antibodies to T15 were specifically inhibited by T15 (F(ab')2 but not by other PC-binding myeloma proteins of different idiotypes. The relationship of the idiotype-specific anti-T15 antibodies to the PC-binding site of the T15 idiotype was analyzed by hapten inhibition of anti-idiotypic binding and by inhibition of BALB/c anti-PC splenic hemolytic plaque formation. Anti-T15 antibodies, for which the T15 binding is inhibited by PC or PC-BSA, also specifically inhibit anti-PC plaque formation. These antibodies are labeled site and near-site anti-idiotypic antibodies. Site and near-site-specific anti-idiotypic antibodies recognize different idiotopes on the T15 molecules. The possible differential biologic activities of these anti-idiotopes in idiotype network regulation is considered.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7033381

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Biological mimicry of antigenic stimulation: analysis of the in vivo antibody responses induced by monoclonal anti-idiotypic antibodies.

Authors:  J Y Huang; R E Ward; H Kohler
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

2.  Human anti-phosphorylcholine antibodies share idiotopes and are self-binding.

Authors:  R Halpern; S V Kaveri; H Köhler
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

3.  Tumor idiotype vaccines. VIII. Analysis of protective idiotype in sera and hybridomas derived from tumor-bearing mice with long-term survival.

Authors:  J J Chen; H Kohler
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

4.  COOH terminus of membrane IgM is essential for an antigen-specific induction of some but not all early activation events in mature B cells.

Authors:  V S Parikh; C Nakai; S J Yokota; R B Bankert; P W Tucker
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

5.  Idiotypic self binding of a dominant germline idiotype (T15). Autobody activity is affected by antibody valency.

Authors:  C Y Kang; H L Cheng; S Rudikoff; H Kohler
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

6.  Point mutations cause the somatic diversification of IgM and IgG2a antiphosphorylcholine antibodies.

Authors:  N C Chien; R R Pollock; C Desaymard; M D Scharff
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

7.  Regulatory idiotopes. Induction of idiotype-recognizing helper T cells by free light and heavy chains.

Authors:  M McNamara; H Kohler
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

8.  Immunoglobulin with complementary paratope and idiotope.

Authors:  C Y Kang; H Kohler
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

9.  Regulatory idiotypes. T helper cells recognize a shared VH idiotope on phosphorylcholine-specific antibodies.

Authors:  K Gleason; H Köhler
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

10.  Invertebrate recognition protein cross-reacts with an immunoglobulin idiotype.

Authors:  G R Vasta; J J Marchalonis; H Kohler
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.